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High-throughput antibody array scan. 





Mammography has become a widely used screening tool for breast cancer. Some studies indicate 
that routine mammographic screening reduces breast cancer mortality by 30% among women 50-69 
years of age; however the magnitude of this mortality benefit remains controversial. Under current 
guidelines, age and sex remain the sole factors used in determining whether or not a mammogram 
screening is recommended. This results in millions of healthy women being frequently imaged and 
biopsied, while other women with cancer falsely identified as cancer-free. More refined methods of 
breast cancer risk assessment that integrate clinical parameters could tailor screening 
recommendations; to-date, no clinically useful blood-based biomarkers have been identified for early 
breast cancer diagnosis. Drs. Matthew Buas, Christopher Li, and colleagues in the Public Health 
Sciences Division sought to detect candidate biomarkers for estrogen receptor positive/progesterone 
receptor positive (ER+/PR+) invasive ductal carcinoma, a subtype that accounts for ~45% of 
invasive breast cancer diagnoses in the U.S. As recently reported in Breast Cancer Research and 
Treatment, the authors, using pre-clinical plasma specimens with a customized antibody-array, 
identified a pool of novel candidate protein biomarkers for ER+/PR+ invasive ductal carcinoma; such 
biomarkers, if validated in independent populations, could be of use in selecting subsets of women 
for increased mammography screening relative to current guidelines.    
 
To identify novel protein biomarkers for ER+/PR+ invasive ductal carcinoma, the researchers 
conducted a nested case-control study within the Women's Health Initiative observational study, a 
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prospective cohort of over 93,000 post-menopausal women in the U.S. For this study, pre-clinical 
plasma specimens, collected up to 12.5 months before diagnosis from 121 breast cancer cases and 
121 matched controls were available; matching covariates included: age, race/ethnicity, body mass 
index, and hormone replacement therapy use. The researchers divided cases and controls equally 
into training and testing sets and interrogated their plasma samples using a customized antibody 
array. Dr. Buas elaborates, "this study made use of an in-house custom-designed antibody array 
platform developed by Dr. Paul Lampe and colleagues at the Fred Hutch, which enables high-
throughput parallel assessment of >2,000 selected plasma proteins. The platform has evolved over 
the last ~8 years and has been successively refined across multiple generations of array fabr ication 
and development. Several papers have been published describing the platform and its 
implementation in biomarker discovery studies." 
 
When comparing cases to their matched controls, the researchers found statistically significant 
mean differences in signal intensity for 37 distinct proteins; these included both known and novel 
proteins in breast cancer pathogenesis. Four markers remained significant after correcting for 
multiple testing: CSF2, RYBP, TFRC, ITGB4. The last two of these markers have been the focus of 
previous breast cancer research. Studies have linked elevated TFRC protein expression in ER+ 
tumors to higher clinical grade, increased proliferative activity, and worse prognosis. Interestingly, 
this study observed lower levels of TFRC protein in the pre-clinical plasma of cases relative to 
controls; it remains uncertain whether reduced levels of circulating TFRC reflect decreased 
abundance of cellular TFRC, particularly in breast tissue. In contrast to TFRC, the other marker 
previously reported, ITGB4, was elevated in the plasma of cases relative to controls. This marker 
has been linked to increased breast tumor size, nuclear grade, and breast cancer progression.  
 
The researchers next determined whether data from The Cancer Genome Atlas (TCGA) might 
provide further support for any of the markers identified. Of the 37 candidate proteins identified, 14 
exhibited significantly altered changes in RNA expression, when comparing breast tumor versus 
normal tissue.  
 
To assess the utility of combining multiple candidate biomarkers into a composite marker panel, the 
researchers conducted multivariate modeling. The mean area under the curve (AUC) of the models 
built using the 39 antibodies was 0.75 with an estimated sensitivity (true positive rate) of ~30% at 
95% specificity (true negative rate). According to the authors, a marker panel achieving such a 
sensitivity and specificity "would have the potential to capture a significant number of additional 
women who are most likely to benefit from mammography, without flooding the system with those 
least likely to need imaging." 
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Breast cancer represents a heterogeneous disease with multiple sub-types, defined by distinct 
histological and molecular features. Dr. Buas describes, "by analyzing plasma isolated from women 
who later went on to develop breast cancer (or did not), we could identify proteins that differed in 
abundance prior to breast cancer diagnosis. These marker candidates require external validation in 
independent study populations, but may hold potential clinical value down the road, for applications 
related to early detection or risk stratification."  
 
Additional Fred Hutch investigators contributing to this project were Dr. Jung-hyun Rho, Xiaoyu Chai, 
Yuzheng Zhang, and Dr. Paul D. Lampe. 
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